Research programme: kallikrein inhibitors - Verseon

Drug Profile

Research programme: kallikrein inhibitors - Verseon

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Verseon
  • Class
  • Mechanism of Action Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic macular oedema; Hereditary angioedema

Most Recent Events

  • 26 Sep 2017 Early research in Diabetic macular oedema in USA (PO)
  • 26 Sep 2017 Preclinical trials in Hereditary angioedema in USA (PO)
  • 01 Jan 2016 Preclinical trials in Diabetic macular oedema in USA (Ophthalmic) (Verseon pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top